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Abstract 
Background: For Glioblastoma (GBM) patients, a number of anti‑neoplastic strategies using specifically targeting 
drugs have been tested; however, the effects on survival have been limited. One explanation could be treatment 
resistance due to redundant signaling pathways, which substantiates the need for combination therapies. In GBM, 
both the epidermal growth factor receptor (EGFR) and the notch signaling pathways are often deregulated and linked 
to cellular growth, invasion and angiogenesis. Several studies have confirmed cross‑talk and co‑dependence of these 
pathways. Therefore, this study aimed at testing a combination treatment strategy using inhibitors targeting the 
notch and EGFR pathways.
Methods: For evaluation of cell viability a standard MTT assay was used. Western blotting (WB) and Q‑RT‑PCR were 
employed in order to assess the protein‑ and mRNA expression levels, respectively. In order to determine angiogenic 
processes, we used an endothelial spheroid sprouting assay. For assessment of secreted VEGF from GBM cells we 
performed a VEGF‑quantikine ELISA.
Results: GBM cells were confirmed to express EGFR and Notch and to have the capacity to induce endothelial cell 
sprouting. Inhibition of EGFR and Notch signaling was achieved using either Iressa (gefitinib) or the gamma‑secretase 
inhibitor DAPT. Our data showed that DAPT combined with Iressa treatment displayed increased inhibitory effect on 
cell viability and abrogated expression and activation of major pro‑survival pathways. Similarly, the combinational 
treatment significantly increased abrogation of GBM‑induced endothelial cell sprouting suggesting reduced GBM 
angiogenesis.
Conclusion: This study finds that simultaneous targeting of notch and EGFR signaling leads to enhanced inhibitory 
effects on GBM‑induced angiogenesis and cell viability, thereby stressing the importance of further evaluation of this 
targeting approach in a clinical setting.
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Background
Glioblastoma (GBM) is a devastating tumor of the brain 
and current therapies have only a palliative effect. GBM 
tumors are proliferative and infiltrative with a promi-
nent angiogenic phenotype [1]. Thus, therapies targeting 
angiogenesis have become interesting in the treatment 
of GBM and the humanized antibody bevacizumab tar-
geting vascular endothelial growth factor A (VEGF) are 
approved for patients with recurrent GBM [2]. However, 
as the effect of this and other anti-angiogenic therapies 
tested in GBM are very limited [3], new alternative strat-
egies for targeting GBM in general and angiogenesis in 
particular are needed.
GBM is often associated with mutation and amplifica-
tion of the epidermal growth factor receptor (EGFR) gene 
and consequently, the importance of EGFR signaling for 
tumor development and maintenance has gained much 
attention [4]. Overexpression of EGFR has been corre-
lated to the malignant phenotype of GBM and the most 
common EGFR mutation in GBM EGFRvIII leads to con-
stitutive active signaling [5–8]. Activation of EGFR down-
stream signaling pathways leads to increased proliferation 
and tumorigenesis, and stimulates angiogenesis via up-
regulation of pro-angiogenic molecules in the tumor 
cells [9, 10]. In line with this finding, anti-EGFR therapies 
have been shown to reduce the production of the pro-
angiogenic factor VEGF and reduce vascular formation 
[11, 12]. Similarly to EGFR, the Notch pathway has also 
gained attention as a potential target in GBM. The notch 
gene family consists of four transmembrane receptors 
(notch1–4) and their ligands (jagged1–2 and Dll1, Dll2 
and Dll4) [13]. Ligand binding to the receptor results in 
two successive proteolytic cleavages which activate down-
stream signaling resulting in transcription of downstream 
targets such as Hes1 and Hey1 [14]. The Notch pathway 
has been linked to a number of GBM specific processes 
including cellular responses to hypoxia, angiogenesis and 
tumor growth [15, 16]. Thus, the Notch pathway repre-
sents a highly interesting therapeutic target.
Increasing evidence points to a cross-talk between the 
Notch and EGFR pathway [17, 18]. In line with this, GBM 
tumors with EGFR amplification display overexpression 
of notch-regulated genes [19] and it has been shown that 
notch signaling can induce EGFR upregulation through 
a P53-dependent mechanism in GBM [20]. It is also 
believed that the interplay between notch and EGFR is 
involved in the genesis and maintenance of tumor cells in 
various cancers including GBM [18, 21]. Thus, this study 
aimed at investigating the functional interplay between 
EGFR and notch signaling and elucidating its role in 
GBM cell maintenance and GBM-induced endothelial 
cell (EC) sprouting as a surrogate marker for angiogene-
sis-like processes.
This was done by evaluating the effect of mono- or 
combined therapy using the tyrosine-kinase inhibitor 
iressa (TKI; targeting EGFR) and the gamma-secretase 
inhibitor DAPT (GSI; targeting notch signaling). In the 
present study, we have used two primary GBM cell cul-
tures with confirmed notch and EGFR expression. Both 
iressa as well as DAPT single-agent treatment abro-
gated EGFR and notch signaling, respectively, leading to 
reduced cell viability, and decreased VEGF expression 
and GBM-induced EC sprouting. Upon combinational 
treatment with both iressa and DAPT, the inhibitory 
effect on cell viability and EC sprouting was even more 
pronounced. Our data indicate that the cross-talk 
between EGFR and Notch signaling pathways are crucial 
for GBM maintenance and vascular phenotype.
Methods
Cell cultures
GBM cell cultures used in this study were CPH036 
(p6) and CPH047 (p3m1). These were established from 
patient tumor tissue derived from initial surgery before 
any other treatment and have previously been described 
in regard to EGFR status and expression of markers 
related to stemness and the neuronal lineages [22]. We 
further analyzed the IDH status of the cell cultures by 
dideoxy sequencing of IDH1 codon 132 and IDH2 codon 
140 and 172. Both cell lines were found to be IDH1/2 
wild-type (unmutated). Cells were cultured as floating 
neurospheres in Neurobasal®-A media (NB media) sup-
plemented with N2, B27, bFGF (10 ng/ml), EGF (10 ng/
ml), l-glutamine, penicillin (50  U/ml), and streptomy-
cin (50 µg/ml) (all from Invitrogen) and incubated in cell 
culture flasks (NUNC) in a humidified chamber with 5 % 
CO2 at 37  °C. Spheres were dissociated at every experi-
ment and at new passage to obtain single cells. Endothe-
lial cells (EC) used in this study represents primary 
human dermal microvascular endothelial cells (HMVEC) 
from Lonza. EC were incubated in endothelial growth 
medium-2 (EGM-2) added EGM-2 microvascular (MV) 
supplements (VEGF, EGF, bFGF, long R3 insulin-like 
growth factor (R3-IGF-1), ascorbic acid, hydrocortisone, 
GA-1000 and 5 % fetal calf serum (FCS); all from Lonza. 
Cells were incubated at 5 % CO2 at 37 °C and passaged at 
sub-confluence.
Reagents
Drugs used in experiments were DAPT (N-[(3,5-difluo-
rophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimeth-
ylethyl ester) obtained from Merck Millipore and iressa 
(Gefitinib) from tocris bioscience. All drugs were dis-
solved in DMSO which was also used for treatment con-
trols. Recombinant human VEGF165 from Miltenyi Biotec 
was used to induce a pro-angiogenic response.
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Western blotting
Protein lysates for western blotting (WB) were prepared 
and obtained from cell pellets by sonication in ice-cold 
modified RIPA buffer [50  mM Tris–HCl (pH 7.4), 1  % 
NP40, 0.25  % Na-deoxycholate, 150  mM NaCl, 1  mM 
EDTA] supplemented with protease and phosphatase 
inhibitor mixture II and III (calbiochem). Determination 
of protein concentrations was done by the BCA protein 
assay (pierce). WB was performed by separation of pro-
tein lysates on NuPage 4–12  % Bis–Tris gels following 
electroblotting onto nitrocellulose membranes using 
the Novex NuPAGE SDS-PAGE gel system (invitrogen). 
Membranes were blocked in 5 % non-fat dry-milk in wash 
buffer for one hour at room temperature following incu-
bation with primary antibodies overnight at 4 °C. Primary 
antibodies used are displayed in Additional file 1: Figure 
S4. The following day membranes were washed and incu-
bated with HRP-conjugated secondary antibodies for 1 h 
at room temperature and developed using the SuperSig-
nal West Dura Extended Duration Substrate (pierce bio-
technology) and the biospectrum imaging system (UVP).
Quantitative real‑time PCR (Q‑RT‑PCR)
Total RNA was purified from GBM cell pellets as pre-
viously described [23]. In short, RNA was obtained by 
using the RNeasy Mini kit and QIAshredder and submit-
ted to a DNase treatment (all from Qiagen). For cDNA 
synthesis and Q-RT-PCR reactions the SuperscriptTM 
III platinum® two step qRT-PCR kit with SYBR® Green 
(Invitrogen) was used. Gene expression levels were quan-
tified according to the comparative Ct method and nor-
malized to expression of the three housekeeping genes 
TOP1, EIF4A2, and CYC1 (primerdesign). Primers used 
in Q-RT-PCR reactions for amplification of target genes 
are displayed in Additional file 1: Figure S5.
Cell viability assay
Cells were plated at concentrations of 2.5–3.5 × 104 cells 
per well in 96-well plates and incubated for 7 days with 
either 100  µl of growth medium or medium containing 
indicated treatments or control. Cell viability was meas-
ured using a 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay (sigma) by the addition 
of 20  µl of MTT solution (5  mg/ml, dissolved in sterile 
water) to each well and incubation for 4  h before the 
addition of 100 µl of solubilization buffer (10 % sodium 
dodecyl sulfate, 0.01 M HCl). Absorbance at 570 nm was 
measured the next day using Synergy2 microplate reader 
with Gen5 software.
VEGF enzyme‑linked immunosorbent assay (ELISA)
One million cells were grown for 14  days in 10  ml of 
culture media added vehicle or inhibitors for 14  days. 
Conditioned media was collected and VEGF (-A) lev-
els were quantified using the Human VEGF Quantikine 
ELISA kit (R&D Systems) following manufacturer’s 
instructions. Quantification was done by measuring the 
absorbance at 450 nm with 570 as a reference using the 
Synergy2 microplate reader.
Spheroid sprouting assay
A spheroid sprouting assay was employed in order to 
assess the angiogenic-like sprouting process in response 
to pro-angiogenic stimulus and principally performed 
as described previously [24]. Cell spheroid formation 
was obtained by seeding 2000 HMVEC (EC) in each 
well in non-adherent round-bottomed 96-well plates in 
growth medium (EGM-2MV) containing 0.3  % methyl-
cellulose (Sigma-Aldrich) and incubated at 37 °C and 5 % 
CO2 for 24 h. Next, the single spheroids from the wells 
were collected and embedded into collagen gels, con-
sisting of a collagen solution (1  mg/ml rat tail collagen 
from BD Biosciences) with 0.2  M NaOH, 1 ×  Medium 
199 (Sigma-Aldrich), 0.6  % methylcellulose, (Sigma-
Aldrich) in HMVEC basal medium (EBM-2), in 4-well 
plates. For each well containing spheres, these were 
stimulated with 50 % FCS in EBM-2 medium added the 
experimental factor. In the cases where this was condi-
tioned media from GBM cells, the media was collected 
from 1 × 106 cells grown for 14 days with or without the 
indicated treatments and subsequently up-concentrated 
around 10 times by centrifugation at max speed using 
Amicon Ultra Centrifugal Filter Units (Merck Millipore). 
Spheres were incubated for 16 h and spheroid sprouting 
was visualized by using an Eclipse TS100 phase-contrast 
microscope, Digital Sight imaging system and the NIS 
Elements F3.2 software (all from Nikon). Quantifica-
tion of spheroid sprouting (number of sprouts and total 
sprout length per sphere) was determined using ImageJ 
software.
Statistics
Statistics were performed using a one-way Analysis of 
Variance test (ANOVA) to compare multiple data groups, 
followed by Tukeys post hoc test, for comparison of mul-
tiple samples or by an un-paired two-tailed student’s t 
test when comparing two samples. The software used for 
the above statistics and creation of figures was Graphpad 
Prism 6.0. The effect of combination therapy was done in 
SAS version 9.4 (SAS Institute, Denmark) by general lin-
ear modeling and analysis of the response levels was done 
on the log scale. Tests for additivity were made by com-
paring the sum of the two treatment effects on the log 
scale with the combination treatment and the hypothesis 
of additive effect were rejected if the comparison demon-
strated significant interaction i.e. evidence of synergistic 
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or sub-additive effect. A p value  <  0.05 was considered 
statistically significant.
Results
Characterization of GBM cell cultures for EGFR‑ and notch 
signaling pathway component expression
Q-RT-PCR and western blotting (WB) were employed 
in order to determine the expression levels of EGFR 
and EGFRvIII and Notch family molecules in two pri-
mary GBM cell cultures (CPH036 and CPH047). Both 
mRNA and protein analysis found that the two cultures 
were positive for EGFR, whereas only CPH047 displayed 
expression of the mutated EGFR variant, EGFRvIII, 
(Fig. 1a, b). Further, mRNA analysis found that both cell 
cultures express notch receptors 1–3 and their notch 
receptor ligands jagged-1, jagged-2, Dll-1 and Dll-4 
(Fig. 1c) and the expression was confirmed when exam-
ining a selection of these molecules at the protein level 
(Fig.  1d). Protein expression of the notch downstream 
effector protein, Hes-1, confirmed active Notch signaling 
in both cultures (Fig. 1d).
Iressa and DAPT abrogates downstream survival pathway 
signaling through the EGFR‑ and notch pathways 
and reduces cell viability in vitro
Following verification that the GBM cells expressed com-
ponents of the EGFR- and notch signaling pathways, 
we wanted to investigate the effect of EGFR and Notch 
inhibition. We used the EGFR inhibitor iressa, and the 
notch inhibitor DAPT for investigating the effect of 
EGFR and notch signaling abrogation on the downstream 
survival kinases Akt and Erk. In CPH036 cells, mono-
therapy with iressa (5 µM) inhibited EGFR phosphoryla-
tion (pY1086) but had no effect on phosphorylation of 
the downstream effector proteins Akt (p-Akt) and Erk 
(p-Erk) as seen in Fig.  2a. DAPT (5  µM) mono-therapy 
had minor effect on p-EGFR and displayed inhibition of 
p-Akt but without effect on p-Erk. Upon combined Iressa 
and DAPT treatment this resulted in both inhibition of 
p-Akt and p-Erk in CPH036 cells. In CPH047 cells mono-
therapy with either Iressa or DAPT reduced p-Akt and 
p-Erk levels to some degree and upon combined treat-
ment this effect was even more pronounced (Fig.  2a). 
Furthermore, as seen in Fig.  2b, mono-therapy, with 
Iressa or DAPT, decreased Hes-1 expression in CPH047 
cells whereas only DAPT could inhibit Hes-1 expression 
in CPH036 cells. Upon combinational treatment with 
Iressa and DAPT an additive downregulation of Hes-1 
expression was seen in CPH047 cells, whereas no direct 
additive effect could be seen in the CPH036 cells.
Following confirmation that the inhibitors abrogated 
downstream signaling through survival pathways Akt 
and Erk, we examined the effect of Iressa and DAPT on 
cell viability in vitro. As seen in Fig. 2c single-agent treat-
ment of the CPH036 cells, with either DAPT or Iressa, 
was able to significantly decrease cell viability compared 
to control. Upon co-administration of both drugs, this 
effect was even further potentiated and confirmed to be 
additive, as a test for additivity was not rejected (p = 0.56 
for 0.5 μM iressa + 5 μM DAPT and p = 0.50 for 2 μM 
Iressa + 20 μM DAPT). In CPH047 cells, higher concen-
trations (20  µM DAPT or 2  µM iressa) of each inhibi-
tor were needed to significantly inhibit cell viability and 
upon combined treatment this inhibitory effect was 
further enhanced and again confirmed to be additive 
(p =  0.98) (Fig.  2d). In conclusion, combinational ther-
apy with Iressa and DAPT display pronounced inhibitory 
effect as compared to mono-therapy in GBM cells on 
both downstream signaling of the EGFR- and notch path-
way and cell viability.
Capacity of GBM cell cultures to secrete and express VEGF 
and to induce endothelial cell sprouting
VEGF is a well-known inducer of angiogenesis in GBM 
[25]. This prompted us to investigate the level of VEGF 
expression and secretion in CPH036 and CPH047 
cells. We found that both cell cultures were positive for 
VEGF mRNA expression and protein secretion (Fig. 3a) 
together with other pro-angiogenic factors (Additional 
file  1: Figure S1). The expression of VEGF receptors 
(VEGFR-1 and -2) could not be detected in the GBM 
cells (Additional file 1: Figure S2), suggesting only parac-
rine effects of VEGF upon secretion from the tumor cells. 
Knowing that the GBM cells secrete VEGF into the cul-
ture media we assessed whether conditioned media from 
CPH036 and CPH047 was sufficient in inducing angio-
genic-like processes in EC. We performed a cell sprout-
ing assay which measures the cells ability to migrate, 
proliferate and form tube-like structures, all processes 
required in angiogenesis. Upon exposure of EC to condi-
tioned media obtained from either CPH036 or CPH047 
cells this clearly induced sprouting as displayed in Fig. 3b. 
The relative number of sprouts per sphere and relative 
total sprout length per sphere was quantified to be sig-
nificantly increased compared to control (NB uncondi-
tioned media) as shown in Fig. 3c, d. These data implied 
that the examined GBM cells have the capacity of induc-
ing angiogenesis-like processes of EC in  vitro possibly 
through secretion of VEGF.
Iressa and DAPT abrogates GBM‑induced endothelial cell 
sprouting and reduces VEGF expression and secretion 
by GBM cells
Following confirmation that the GBM cells displayed 
capacity to induce EC sprouting, we investigated how 
this ability was affected by EGFR and Notch inhibition. 
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EC were subjected to conditioned media collected from 
GBM cells receiving either no treatment (DMSO) or 
treatment with 5  µM iressa and 5  µM DAPT alone or 
in combination (5  µM DAPT +5  µM iressa). We found 
that mono-therapy with Iressa or DAPT of CPH036 and 
CPH047 cells significantly reduced the capacity of GBM-
induced EC spheroid sprouting (Fig.  4a–c, e). Upon 
treatment with combined DAPT and iressa an increased 
co-inhibitory effect of quantified EC sprouting could be 
seen compared to mono-therapy (Fig. 4c, e). In CPH036 
cells, the co-inhibitory effect was confirmed to be addi-
tive for both the number (p = 0.62) and length (p = 0.59) 
of spouts. For the CPH047 cells the length of spouts was 
borderline non-significant (p =  0.080), demonstrating a 
trend towards additivity. Conversely, the co-inhibitory 
effect for the number of sprouts in CPH047 cells showed 
a significant interaction (p  =  0.046), but with an effect 
that was less (76  % reduction) than would be expected 
if additive (83  % reduction), suggesting that the combi-
nation was sub-additive. Further, the inhibitory effect of 
DAPT and Iressa on EC sprouting could be confirmed 
not to be a result of non-metabolized inhibitor leftovers 
inducing EC death since conditioned media from GBM 
cells treated with DAPT, Iressa or a combination had no 
Fig. 1 Expression levels of EGFR and notch molecules in two primary GBM cell cultures (CPH036 and CPH047). a, c Q‑RT‑PCR detection of EGFR, 
EGFRvIII, notch 1–3, jagged 1–2, Dll‑1 and Dll‑4 mRNA expression in CPH036 and CPH047 cells. EGFRvIII was not detected (ND) in CPH036 cells 
(mean ± SEM, n = 3). b, d WB analysis of EGFR, EGFRvIII, notch 1‑ and ‑3, Dll‑4 and Hes‑1 protein in CPH036 and CPH047 cells. Tubulin serves as 
loading control
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effect on EC proliferation (Additional file  1: Figure S3). 
To examine whether the effect of inhibited GBM-induced 
EC sprouting could be due to the effect of Iressa and 
DAPT on VEGF expression and secretion by the GBM 
cells, we measured VEGF secretion following treatment. 
Iressa treatment resulted in almost complete inhibition of 
VEGF expression and secretion in CPH036 and CPH047 
cells (Fig. 4d, f ), while DAPT treatment was able to par-
tially abrogate VEGF expression and secretion, however 
with less potency, compared to iressa. Upon combined 
treatment no additive effect could be observed as a result 
of almost complete inhibition of VEGF secretion and 
expression by Iressa treatment (Fig.  4d, f ). Summed, 
both iressa and DAPT display capacity to inhibit GBM-
induced cell sprouting in EC and upon combinational 
treatment this effect is even further enhanced. Further, 
the results indicate that this effect, at least partly, could 
be a result of inhibition of VEGF expression.
Discussion
EGFR and notch are both involved in regulation of 
GBM cancer cells by promoting their survival, thera-
peutic resistance and pro-angiogenic signaling [13, 26, 
27]. Thus, there is a rationale for treatment with inhibi-
tors targeting both the EGFR and Notch signaling axis 
in GBM. The main focus of this study was to investigate 
the effect of simultaneous EGFR and notch abrogation on 
GBM cell maintenance and EC sprouting.
Aberrant expression of components of the EGFR and 
notch pathway has in GBM been confirmed previously [27, 
Fig. 2 Iressa and DAPT treatment inhibits the EGFR‑ and notch pathways abrogating downstream signaling and cell viability in vitro. a, b WB analy‑
sis of CPH36 and CPH047 cells treated with 5 µM iressa, 5 µM DAPT or a combination for 24 h. WB was investigated for expression of EGFR, EGFRvIII, 
Akt, p‑Akt, Erk, p‑Erk and Hes‑1. GAPDH and tubulin serves as loading controls. c, d Cell viability of CPH036 or CPH047 cells following 7 days of treat‑
ment with iressa, DAPT or a combination in the indicated doses (mean ± SEM, n = 5). *p < 0.05, **p < 0.01, ***p < 0.001
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28]. In accordance with this, we identified heterogeneous 
expression of EGFR/EGFRvIII, notch ligands and notch 
receptors in our GBM cell cultures. EGFR and Notch are 
important regulators of angiogenesis and abrogation of 
either of these pathways results in reduced angiogenesis in 
GBM [15, 29]. In the examined GBM cells, we confirmed 
endogenous expression and secretion of the key pro-angi-
ogenic cytokine VEGF [25], for which increased expression 
has been correlated with increased glioma malignancy and 
poor prognosis [30, 31]. Furthermore, we confirmed that 
the examined GBM cells were able to induce EC sprouting 
(Fig. 3b–d) indicating that these cells had the capacity to 
induce neo-angiogenesis of surrounding EC by the secre-
tion of pro-angiogenic factors.
Upon abrogation of Notch and EGFR signaling by 
DAPT or Iressa treatment, respectively, this inhibited 
the expression and secretion of VEGF in our GBM cells 
(Fig. 4d, f ). This supports that VEGF-induced angiogen-
esis is dependent of active signaling through the notch 
and EGFR pathways as also shown by others [32–34]. 
Recently, Wang et  al. [29] showed that combined treat-
ment with the anti-EGFR antibody Cetuximab together 
with DAPT displayed downregulation of VEGF in Head 
Neck Squamous Cell Carcinoma [29], which is in line 
with our observations. VEGF is generally considered to 
be a positive upstream regulator of Notch with Notch 
acting as an upstream regulator of VEGFRs [35]. More-
over, our data demonstrate that Notch regulates VEGF 
Fig. 3 EC cell sprouting stimulation by GBM‑conditioned cell culture media. CPH036 and CPH047 cells were grown for 14 days and the condi‑
tioned media was collected and concentrated. EC were grown in presence of 20 ng/ml VEGF or conditioned media from CPH036 or CPH047 cells. 
a Relative VEGF expression analyzed by Q‑RT‑PCR, and VEGF secretion (ng/ml) analyzed by ELISA of CPH036 and CPH047 cells (mean ± SEM, n = 6 
for Q‑RT‑PCR and n = 3 for ELISA). b Representative pictures showing sprouting of EC upon stimulation with VEGF or conditioned media from 
either CPH036 or CPH047 cells. c, d EC sprouting quantified as number of sprouts and total length of sprouts per sphere, respectively, and displayed 
relative to NB unconditioned media (mean ± SEM, n = 3 measuring an average of 10 spheres per condition in each experiment). Scale bar shows 
100 μm. ***p < 0.001 vs. NB medium
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expression, indicating the existence of a positive feed-
back-loop regulatory mechanism.
Studies have shown that treatment with small molecule 
inhibitors targeting EGFR or Notch is able to inhibit GBM 
angiogenesis in vitro [36, 37]. We observed that treatment 
with DAPT plus iressa was not sufficient to fully block EC 
sprouting (Fig.  4c, e) despite almost complete inhibition 
of VEGF secretion upon combined treatment (Fig. 4d, f ) 
Fig. 4 Iressa and DAPT treatment abrogates GBM‑induced EC sprouting, and inhibits VEGF expression and secretion in GBM cells. CPH036 and 
CPH047 cells were treated with 5 µM iressa, 5 µM DAPT or a combination for 14 days. The conditioned GBM media was concentrated and subjected 
to EC for sprouting analysis. a, b Representative pictures showing sprouting of EC upon administration of conditioned media obtained from CPH036 
or CPH047 cells treated with indicated inhibitors. c, e Relative EC sprouting quantified as total number of sprouts and total length of sprouts per 
sphere upon stimulation with conditioned inhibitor‑treated media from either CPH036 or CPH047 cells, respectively (mean ± SEM, n = 3 measuring 
an average of 10 spheres per condition in each experiment). d, f VEGF mRNA levels in inhibitor‑treated CPH036 and CPH047 cells were analyzed 
by Q‑RT‑PCR and normalized to the mean gene expression of the control. VEGF secretion levels (ng/ml) analyzed by ELISA from inhibitor‑treated 
CPH036 and CPH047 cells as measured by VEGF‑ELISA (mean ± SEM, n = 3). Scale bar shows 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001
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suggesting that other angiogenic stimulators are involved 
in GBM-induced EC sprouting. Factors including angio-
genin, PDGF-AA, IGFBP-3 are known to be implicated in 
angiogenesis [38–40] and were confirmed to be present 
in the GBM-conditioned media at comparable levels to 
VEGF (Additional file  1: Figure S1) which could explain 
additional stimulation of EC sprouting.
Aberrant EGFR and notch signaling regulate cell viability 
and therapeutic resistance of GBM cells [17, 27, 41]. Both, 
EGFR and notch regulated signaling are in GBM linked to 
the RAS-RAF-MEK-ERK and the PI3K-Akt-mTOR signal-
ing pathways [42, 43]. Interestingly, it has been shown that 
Notch signaling is dependent on mTOR in lung and kid-
ney tumor cells [44], indicating the existence of a positive 
feedback loop between Notch and EGFR signaling. Our 
results show that the inhibition of EGFR signaling results 
in decreased Hes-1 levels supporting that EGFR signaling 
stimulate activity of the Notch pathway. Further, we found 
upon combined treatment targeting both Notch and EGFR 
an increased inhibition of GBM cell viability compared to 
mono-therapy alone. This was probably a result of more 
effective inhibition of the pro-survival pathways Akt and 
Erk which we observed upon combination therapy (Fig. 2a). 
Cenciarelli et al. [28] showed that co-treatment with GSI-X 
and AG1478 (targeting Notch and EGFR, respectively) dis-
played synergistic anti-proliferative effects in GBM in vitro 
[28]. Taken together, our data and those of others indicate 
redundant signaling between EGFR and Notch, which indi-
cate a need for further preclinical and clinical evaluation 
of simultaneous inhibition of Notch and EGFR which are 
upstream of key pro-survival regulatory pathways as the 
RAS-RAF-MEK-ERK and PI3K-Akt-mTOR.
Over the last years, a number of pharmacological studies 
have been conducted testing either EGFR or Notch path-
way inhibitors in patients with various cancer types includ-
ing GBM (http://www.clinicaltrial.gov). For GBM patients a 
number of different EGFR targeting drugs have been tested 
in the clinic, but overall results have been disappointing 
with non or very limited clinical benefits [45]. So far, only 
one study has been reported for the use of a notch-specific 
inhibitor in glioma patients. In this study, the Merck-devel-
oped GSI termed MK-0752 was tested in various advanced 
solid tumors and the results indicated some clinical ben-
efits especially in glioma patients [46]. Still, the anti-tumor 
activity was not impressive with most patients obtaining 
stable disease as best response [46]. Data from a currently 
ongoing phase II trial, treating patients with recurrent or 
progressive GBM with another GSI (RO4929097), are yet 
to be published, but will further shed light on the effect of 
single-agent treatment with Notch inhibitors. Overall, the 
results from recent and/or ongoing clinical trials evaluat-
ing EGFR- and notch-specific inhibitors as mono-therapies 
imply certain clinical limitations of this approach.
In this study, we find that a combined treatment strat-
egy that targets both EGFR and notch signaling pathways 
results in enhanced inhibitory effect on cell viability and 
EC sprouting, compared to either of the mono-therapies, 
supporting the important role of notch/EGFR signal-
ing cross-talk in GBM. Taken together, this fact and the 
above mentioned clinical studies support the rationale 
for combined treatment strategy employing both EGFR 
and notch inhibitors.
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